We then demonstrated that CBX-12 was active in two additional flank tumor xenograft models, JIMT-1 (breast cancer, intermediate HER2 expression) and MKN45 (gastric cancer, HER2 negative), using either a two or three dosing cycle regimen as presented above. This evidence concerns the gene ERBB2 and neoplasm.